NCT00079495View on ClinicalTrials.gov

Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 31, 2003

Study Completion Date

April 30, 2005

Conditions
Multiple Sclerosis
Interventions
DRUG

NBI-5788

Sponsors
All Listed Sponsors
collaborator

Immune Tolerance Network (ITN)

NETWORK

lead

Neurocrine Biosciences

INDUSTRY